The short version.
If you're searching for NAD+ for longevity, you've probably read the David Sinclair / Charles Brenner / Eric Verdin work. The argument: NAD+ levels decline with age, sirtuins (which depend on NAD+) regulate stress response and metabolic health, PARP enzymes consume NAD+ during DNA repair, and restoring NAD+ pools may slow several aging-related processes.
That story is biologically real and partly proven. The question — and it's worth being honest about — is how much of the mouse-and-yeast data carries over to humans on a typical clinical schedule. The longevity case for NAD+ is plausible. The case that exogenous NAD+ extends human healthspan in measurable ways is still under construction.
What the literature actually says.
Strongest signals: NAD+ precursors elevate blood NAD+ in humans. Several small trials have shown improvements in markers like blood pressure, exercise capacity, or muscle metrics in older adults. The Imai and Sinclair labs have shown striking effects in aged mice — improved muscle function, mitochondrial restoration, sometimes lifespan changes — but mouse-to-human extrapolation in longevity work has been disappointing more often than not.
Where the evidence is weak: there is no human RCT showing that NAD+ supplementation extends lifespan or healthspan in the way the marketing implies. There are biomarker effects, suggestive small-trial results, and a strong mechanistic story. That's a foundation, not a finished case.
The honest framing: NAD+ is one of the better-supported "longevity" molecules in the sense that the mechanism is real, the decline-with-age signal is real, and replacement raises blood levels. Whether the resulting downstream effects translate into a longer healthspan for any individual is exactly the kind of question longevity research takes decades to answer.
The longevity case for NAD+ is plausible. The case that it extends human healthspan in measurable ways is still under construction.
Why oversight matters.
The internet sells almost any peptide as research chemicals — vials with disclaimers, no prescription, no provider, no follow-up. The risk isn't theoretical. Sterility, peptide identity, peptide content, and contamination all vary widely between gray-market vendors. The FDA has been explicit that compounded drugs aren't FDA-approved, and that research-only labels don't protect consumers when products end up in human use.
Oversight isn't a bureaucratic checkbox. It's a U.S.-licensed prescriber who reviews your history before prescribing, a 503A compounding pharmacy that sources active pharmaceutical ingredient and prepares the medication under USP 797 sterile standards, and a follow-up cadence that lets someone catch a problem before it becomes a worse one.
How Boswell handles this.
Boswell pairs you with a U.S.-licensed physician for the intake. They review your goals, medications, history, and any contraindications before prescribing. If a protocol isn't appropriate, you don't get it. If it is, the prescription goes to a 503A compounding pharmacy that prepares the medication under sterile compounding standards, labels it for you specifically, and ships it directly.
Refills aren't automatic — they involve a check-in. The point isn't to gate access; it's to keep someone clinical in the loop while you're on therapy. How Boswell works →
Questions worth asking your provider.
- Given my age and labs, what's the realistic case for adding NAD+ now versus waiting?
- Should I prioritize a precursor (NR, NMN) versus direct NAD+ administration?
- What biomarkers will we track — and what would tell us to change course?
- How does NAD+ fit alongside other longevity-relevant interventions (sleep, training, lipids)?
- What's a reasonable trial period before reassessing?
Sources